Chinese Journal of Dermatology ›› 2025, e0250045.doi: 10.35541/cjd.20250045
• Guidelines and Consensus • Previous Articles
Chinese Society of Dermatology; Chinese Dermatologist Association
Received:
2025-01-24
Revised:
2025-06-17
Online:
2025-03-12
Published:
2025-09-24
Contact:
Geng Songmei; Wang Gang
E-mail:gengsongmei73@163.com; xjwgang@fmmu.edu.cn
Chinese Society of Dermatology, Chinese Dermatologist Association. Expert consensus on diagnosis and treatment of pyoderma gangrenosum (2025 edition)[J]. Chinese Journal of Dermatology,2025,e0250045. doi:10.35541/cjd.20250045
[1] | Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction⁃GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011,64(4):383⁃394. doi: 10.1016/j.jclinepi.2010.04.026. |
[2] | Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: an age⁃ and sex⁃adjusted population analysis[J]. J Am Acad Dermatol, 2020,83(2):425⁃429. doi: 10.1016/j.jaad.2019.08.001. |
[3] | Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study[J]. J Invest Dermatol, 2012,132(9):2166⁃2170. doi: 10.1038/jid.2012.130. |
[4] | Kikuchi N, Hiraiwa T, Ohashi T, et al. Pyoderma gangrenosum possibly triggered by adalimumab[J]. Eur J Dermatol, 2012,22(6):804⁃805. doi: 10.1684/ejd.2012.1849. |
[5] | Pollack IR, Wolner ZJ, Hammett J, et al. Pyoderma gangrenosum in a patient on ixekizumab[J]. JAAD Case Rep, 2021,16:152⁃154. doi: 10.1016/j.jdcr.2021.08.021. |
[6] | Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma ⁃ simultaneous occurrence of pyoderma gangrenosum and colitis[J]. Eur J Dermatol, 2014,24(2):268⁃269. doi: 10.1684/ejd.2014.2297. |
[7] | Wu BC, Patel ED, Ortega⁃Loayza AG. Drug⁃induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum[J]. Br J Dermatol, 2017,177(1):72⁃83. doi: 10.1111/bjd.15193. |
[8] | Akahoshi⁃Ikeda M, Yoshizawa S, Motoshita J, et al. A case of pyoderma gangrenosum in a patient with rheumatoid arthritis treated with abatacept[J]. Acta Derm Venereol, 2016,96(6):822⁃823. doi: 10.2340/00015555⁃2380. |
[9] | Lim RK, Negbenebor NA, Lin EM, et al. Cocaine-induced pyoderma gangrenosum with negative anti-neutrophil cytoplasmic antibodies: a case report[J]. Int J Dermatol Venerol, 2023. doi:10.1097/JD9.0000000000000332. |
[10] | Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab[J]. Arch Dermatol, 2011,147(10):1203⁃1205. doi: 10.1001/archdermatol.2011.168. |
[11] | Caproni M, Antiga E, Volpi W, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum[J]. Br J Dermatol, 2015,173(1):275⁃278. doi: 10.1111/bjd.13670. |
[12] | Wang EA, Steel A, Luxardi G, et al. Classic ulcerative pyoderma gangrenosum is a T cell⁃mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies[J]. Front Immunol, 2017,8:1980. doi: 10.3389/fimmu.2017.01980. |
[13] | Nesterovitch AB, Gyorfy Z, Hoffman MD, et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses[J]. Am J Pathol, 2011,178(4):1434⁃1441. doi: 10.1016/j.ajpath. 2010.12.035. |
[14] | Nesterovitch AB, Hoffman MD, Simon M, et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum[J]. Clin Exp Dermatol, 2011,36(8):889⁃895. doi: 10.1111/j.1365⁃2230.2011.04137.x. |
[15] | Moura RR, Brandão L, Moltrasio C, et al. Different molecular pathways are disrupted in pyoderma gangrenosum patients and are associated with the severity of the disease[J]. Sci Rep, 2023,13(1):4919. doi: 10.1038/s41598⁃023⁃31914⁃z. |
[16] | Takeuchi F, Sterilein RD, Hall RP 3rd. Increased E⁃selectin, IL⁃8 and IL⁃10 gene expression in human skin after minimal trauma[J]. Exp Dermatol, 2003,12(6):777⁃783. doi: 10.1111/j.0906⁃6705.2003.00088.x. |
[17] | Maverakis E, van den Elzen P, Sercarz EE. Self⁃reactive T cells and degeneracy of T cell recognition: evolving concepts⁃from sequence homology to shape mimicry and TCR flexibility[J]. J Autoimmun, 2001,16(3):201⁃209. doi: 10.1006/jaut.2000.0493. |
[18] | Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil⁃derived proteases escalate inflammation through activation of IL⁃36 family cytokines[J]. Cell Rep, 2016,14(4):708⁃722. doi: 10. 1016/j.celrep.2015.12.072. |
[19] | Foster AM, Baliwag J, Chen CS, et al. IL⁃36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin[J]. J Immunol, 2014,192(12):6053⁃6061. doi: 10.4049/jimmunol. 1301481. |
[20] | Rubas K, Reich A, Nowicka⁃Suszko D, et al. The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum[J]. J Eur Acad Dermatol Venereol, 2023,37(5):e660⁃e662. doi: 10.1111/jdv.18683. |
[21] | Gaffen SL, Jain R, Garg AV, et al. The IL⁃23⁃IL⁃17 immune axis: from mechanisms to therapeutic testing[J]. Nat Rev Immunol, 2014,14(9):585⁃600. doi: 10.1038/nri3707. |
[22] | Li S, Ying S, Fang H, et al. Gasdermin D⁃dependent neutrophil extracellular traps exacerbate cytokine storm contributing to pyoderma gangrenosum pathogenesis[J]. iScience, 2025,28(3):111925. doi: 10.1016/j.isci.2025.111925. |
[23] | Yamamoto T, Yamasaki K, Yamanaka K, et al. Clinical guidance of pyoderma gangrenosum 2022[J]. J Dermatol, 2023,50(9):e253⁃e275. doi: 10.1111/1346⁃8138.16845. |
[24] | Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum[J]. Nat Rev Dis Primers, 2020,6(1):81. doi: 10.1038/s41572⁃020⁃0213⁃x. |
[25] | Tolkachjov SN, Fahy AS, Wetter DA, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014[J]. J Am Acad Dermatol, 2015,73(4):615⁃622. doi: 10.1016/j.jaad.2015.06.054. |
[26] | Kechichian E, Haber R, Mourad N, et al. Pediatric pyoderma gangrenosum: a systematic review and update[J]. Int J Dermatol, 2017,56(5):486⁃495. doi: 10.1111/ijd.13584. |
[27] | Steele RB, Nugent WH, Braswell SF, et al. Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment[J]. Br J Dermatol, 2016,174(1):77⁃87. doi: 10.1111/bjd.14230. |
[28] | Kikuchi N, Hanami Y, Miura T, et al. Pyoderma gangrenosum following surgical procedures[J]. Int J Dermatol, 2010,49(3):346⁃348. doi: 10.1111/j.1365⁃4632.2009.04201.x. |
[29] | Lekwuttikarn R, Teng J. Cutaneous manifestations of nutritional deficiency[J]. Curr Opin Pediatr, 2018,30(4):505⁃513. doi: 10. 1097/MOP.0000000000000652. |
[30] | Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review[J]. J Cutan Pathol, 2003,30(2):97⁃107. doi: 10.1034/j. 1600⁃0560.2003.00024.x. |
[31] | Jorizzo JL, Solomon AR, Zanolli MD, et al. Neutrophilic vascular reactions[J]. J Am Acad Dermatol, 1988,19(6):983⁃1005. doi: 10.1016/s0190⁃9622(88)70264⁃9. |
[32] | Magro CM, Crowson AN. The cutaneous neutrophilic vascular injury syndromes: a review[J]. Semin Diagn Pathol, 2001,18(1):47⁃58. |
[33] | Quimby SR, Gibson LE, Winkelmann RK. Superficial granulomatous pyoderma: clinicopathologic spectrum[J]. Mayo Clin Proc, 1989,64(1):37⁃43. doi: 10.1016/s0025⁃6196(12)65301⁃4. |
[34] | Wilson⁃Jones E, Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum[J]. J Am Acad Dermatol, 1988,18(3):511⁃521. doi: 10.1016/s0190⁃9622(88)70074⁃2. |
[35] | 胡清洁, 周敏, 姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较[J]. 中华皮肤科杂志, 2023,56(5):410⁃414. doi: 10.35541/cjd.20220825. |
[36] | Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta⁃analysis[J]. Am J Clin Dermatol, 2018,19(4):479⁃487. doi: 10.1007/s40257⁃018⁃0356⁃7. |
[37] | 江燕云, 李骥, 李玥, 等. 溃疡性结肠炎并发坏疽性脓皮病八例研究[J]. 中华皮肤科杂志, 2017,50(9):623⁃625. doi: 10. 3760/cma.j.issn.0412⁃4030.2017.09.001. |
[38] | 许秋云, 纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 2025, 58 (4): 369⁃373. doi: 10.35541/cjd.20240424. |
[39] | Montagnon CM, Fracica EA, Patel AA, et al. Pyoderma gangrenosum in hematologic malignancies: A systematic review[J]. J Am Acad Dermatol, 2020,82(6):1346⁃1359. doi: 10.1016/j.jaad.2019.09.032. |
[40] | Marzano AV, Borghi A, Wallach D, et al. A comprehensive review of neutrophilic diseases[J]. Clin Rev Allergy Immunol, 2018,54(1):114⁃130. doi: 10.1007/s12016⁃017⁃8621⁃8. |
[41] | Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment[J]. Am J Clin Dermatol, 2017,18(4):555⁃562. doi: 10.1007/s40257⁃017⁃0265⁃1. |
[42] | Kastner DL, Aksentijevich I, Goldbach⁃Mansky R. Autoinflammatory disease reloaded: a clinical perspective[J]. Cell, 2010,140(6):784⁃790. doi: 10.1016/j.cell.2010.03.002. |
[43] | Satoh TK, Mellett M, Contassot E, et al. Are neutrophilic dermatoses autoinflammatory disorders?[J]. Br J Dermatol, 2018,178(3):603⁃613. doi: 10.1111/bjd.15105. |
[44] | Janowska A, Papa G, Romanelli M, et al. 5% Lidocaine hydrochloride cream for wound pain relief: a multicentre observational study[J]. J Invest Surg, 2022,35(1):49⁃52. doi: 10.1080/08941939.2020.1821134. |
[45] | Holman M. Using tap water compared with normal saline for cleansing wounds in adults: a literature review of the evidence[J]. J Wound Care, 2023,32(8):507⁃512. doi: 10.12968/jowc. 2023.32.8.507. |
[46] | Lee FG, Song E, Wallace SJ, et al. Non⁃surgical management of complex refractory pyoderma gangrenosum with negative pressure wound therapy with instillation[J]. Cureus, 2021,13(10):e18951. doi: 10.7759/cureus.18951. |
[47] | Hodson EL, Kranyak A, Salem I, et al. Adjunctive hyperbaric oxygen treatment for challenging pyoderma gangrenosum cases[J]. J Tissue Viability, 2024,33(3):449⁃451. doi: 10.1016/j.jtv.2024.06.001. |
[48] | Cohen PR. Neutrophilic dermatoses: a review of current treatment options[J]. Am J Clin Dermatol, 2009,10(5):301⁃312. doi: 10.2165/11310730⁃000000000⁃00000. |
[49] | Lyon CC, Smith AJ, Griffiths CE, et al. Peristomal dermatoses: a novel indication for topical steroid lotions[J]. J Am Acad Dermatol, 2000,43(4):679⁃682. doi: 10.1067/mjd.2000.106237. |
[50] | Wenzel J, Gerdsen R, Phillipp⁃Dormston W, et al. Topical treatment of pyoderma gangraenosum[J]. Dermatology, 2002,205(3):221⁃223. doi: 10.1159/000065843. |
[51] | Al Ghazal P, Dissemond J. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts[J]. J Dtsch Dermatol Ges, 2015,13(4):317⁃324. doi: 10.1111/ddg.12585. |
[52] | Jain AG, Sharbatji M, Afzal A, et al. Pyoderma gangrenosum in the absence of any underlying predisposing condition: a diagnostic dilemma[J]. Cureus, 2019,11(3):e4213. doi: 10. 7759/cureus.4213. |
[53] | Marzano AV, Trevisan V, Lazzari R, et al. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum[J]. J Dermatolog Treat, 2010,21(3):140⁃143. doi: 10.3109/09546630903268239. |
[54] | Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study[J]. J Am Acad Dermatol, 2016,75(5):940⁃949. doi: 10.1016/j.jaad.2016.06.016. |
[55] | Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review[J]. Acta Derm Venereol, 2015,95(5):525⁃531. doi: 10. 2340/00015555⁃2008. |
[56] | Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment[J]. Expert Rev Clin Immunol, 2018,14(3):225⁃233. doi: 10.1080/1744666X.2018.1438269. |
[57] | Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment[J]. Am J Clin Dermatol, 2017,18(3):355⁃372. doi: 10.1007/s40257⁃017⁃0251⁃7. |
[58] | Partridge A, Bai JW, Rosen CF, et al. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials[J]. Br J Dermatol, 2018,179(2):290⁃295. doi: 10.1111/bjd.16485. |
[59] | Kolios A, Gübeli A, Meier B, et al. Clinical disease patterns in a regional swiss cohort of 34 pyoderma gangrenosum patients[J]. Dermatology, 2017,233(4):268⁃276. doi: 10.1159/000481432. |
[60] | Mekkes JR. Treatment of pyoderma gangrenosum[J]. BMJ, 2015,350:h3175. doi: 10.1136/bmj.h3175. |
[61] | 臧箫, 李洪达, 刘永霞, 等. 阿达木单抗治疗坏疽性脓皮病一例并文献复习[J]. 中国麻风皮肤病杂志, 2023,39(1):15⁃17. doi: 10.12144/zgmfskin202301015. |
[62] | Wu Z, Xu QY, Yao ZR. Recalcitrant pediatric pyoderma gangrenosum controlled with adalimumab[J]. Int J Dermatol Venerol, 2022. doi: 10.1097/JD9.0000000000000258. |
[63] | McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report[J]. SAGE Open Med Case Rep, 2020,8:2050313X20940430. doi: 10.1177/2050313X20940430. |
[64] | Tee MW, Avarbock AB, Ungar J, et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy[J]. JAAD Case Rep, 2020,6(11):1167⁃1169. doi: 10.1016/j.jdcr.2020. 08.033. |
[65] | Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum[J]. Am J Gastroenterol, 2012,107(5):794⁃795. doi: 10.1038/ajg.2012.42. |
[66] | Burgdorf B, Schlott S, Ivanov IH, et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab[J]. Int Wound J, 2020,17(4):1086⁃1088. doi: 10.1111/iwj.13359. |
[67] | Baier C, Barak O. Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum[J]. JAAD Case Rep, 2021,8:43⁃46. doi: 10.1016/j.jdcr.2020.12.005. |
[68] | Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin⁃1 receptor antagonist anakinra[J]. Br J Dermatol, 2009,161(5):1199⁃1201. doi: 10.1111/j.1365⁃2133.2009.09404.x. |
[69] | Geusau A, Mothes⁃Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA⁃like syndrome responding to canakinumab treatment[J]. JAMA Dermatol, 2013,149(2):209⁃215. doi: 10.1001/2013.jamadermatol.717. |
[70] | Choong DJ, Ng JL, Vinciullo C. Pyoderma gangrenosum associated with Takayasu's arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab[J]. JAAD Case Rep, 2021,9:4⁃6. doi: 10.1016/j.jdcr.2020.12.034. |
[71] | Ma L, Chen X, Guo Q, et al. Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum[J]. Clin Exp Dermatol, 2023,49(1):82⁃84. doi: 10.1093/ced/llad317. |
[72] | Guénin SH, Khattri S, Lebwohl MG. Spesolimab use in treatment of pyoderma gangrenosum[J]. JAAD Case Rep, 2023,34:18⁃22. doi: 10.1016/j.jdcr.2023.01.022. |
[73] | Ehrl DC, Heidekrueger PI, Broer PN. Pyoderma gangrenosum after breast surgery: a systematic review[J]. J Plast Reconstr Aesthet Surg, 2018,71(7):1023⁃1032. doi: 10.1016/j.bjps.2018. 03.013. |
[74] | Ebrad S, Severyns M, Benzakour A, et al. Pyoderma gangrenosum after orthopaedic or traumatologic surgery: a systematic revue of the literature[J]. Int Orthop, 2018,42(2):239⁃245. doi: 10.1007/s00264⁃017⁃3672⁃2. |
[75] | Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum[J]. Clin Exp Dermatol, 2021,46(6):1082⁃1085. doi: 10.1111/ced.14683. |
[76] | Scheinberg M, Machado LA, M Castro LG, et al. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor[J]. J Transl Autoimmun, 2021,4:100099. doi: 10.1016/j.jtauto.2021.100099. |
[77] | Laird ME, Tong LX, Lo Sicco KI, et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum[J]. JAAD Case Rep, 2017,3(3):228⁃229. doi: 10.1016/j.jdcr. 2017.02.019. |
[78] | Sood AK, McShane DB, Googe PB, et al. Successful treatment of PAPA syndrome with dual adalimumab and tacrolimus therapy[J]. J Clin Immunol, 2019,39(8):832⁃835. doi: 10.1007/s10875⁃019⁃00685⁃6. |
[79] | Foley CC, Laing M. Paraneoplastic pyoderma gangrenosum successfully treated with minocycline and low⁃dose steroids[J]. J Eur Acad Dermatol Venereol, 2015,29(1):184⁃185. doi: 10. 1111/jdv.12384. |
[80] | Yamanaka K, Murota H, Goto H, et al. Pyoderma gangrenosum and annular erythema associated with Sjögren's syndrome controlled with minocycline[J]. J Dermatol, 2015,42(8):834⁃836. doi: 10.1111/1346⁃8138.12897. |
[81] | Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen[J]. Cutis, 1996,57(5):315⁃319. |
[82] | 袁玉婷, 陈瑜, 李莹, 等. 坏疽性脓皮病中西医治疗概述[J]. 中华中医药杂志, 2017,32(8):3614⁃3617. |
[83] | 孟建霞, 徐旭英, 王萍, 等. 培本固元法治愈坏疽性脓皮病[J]. 中华中医药杂志, 2018,33(10):4480⁃4482. |
[84] | 杨曦, 史哲新. 骨髓增生异常综合征合并坏疽性脓皮病1例并文献复习[J]. 白血病•淋巴瘤, 2024,33(6):365⁃368. doi: 10.3760/cma.j.cn115356⁃20220801⁃00222. |
[85] | Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series[J]. Br J Dermatol, 2018,178(2):363⁃368. doi: 10.1111/bjd.15850. |
[86] | 张航, 董慧婷. 增殖型坏疽性脓皮病一例[J]. 中华皮肤科杂志, 2017,50(9):657. doi: 10.3760/cma.j.issn.0412⁃4030.2017.09. 009. |
[87] | Din RS, Tsiaras WG, Li DG, et al. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review[J]. J Drugs Dermatol, 2018,17(10):1058⁃1060. |
[88] | Rampal P, Benzaken S, Schneider S, et al. Colchicine in pyoderma gangrenosum[J]. Lancet, 1998,351(9109):1134⁃1135. doi: 10.1016/S0140⁃6736(05)79420⁃4. |
[89] | Vacas AS, Torre AC, Bollea⁃Garlatti ML, et al. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients[J]. Int J Dermatol, 2017,56(4):386⁃391. doi: 10.1111/ijd.13591. |
[1] | Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of an antioxidant gel containing tea polyphenols combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(9): 834-838. |
[2] | Jiang Qian, Hu Bin, Chen Yao, Chen Liuqing. Acquired facial hyperpigmented macules in children: a retrospective analysis of clinical and skin imaging features in 131 cases [J]. Chinese Journal of Dermatology, 2025, 58(9): 843-847. |
[3] | Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2025, 58(9): 882-885. |
[4] | Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong. Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai [J]. Chinese Journal of Dermatology, 2025, 58(9): 808-815. |
[5] | Jiang Ziqi, Zhong Judan, Chen Tingqiao, Chen Jin. Pathogenesis and treatment of melasma [J]. Chinese Journal of Dermatology, 2025, 58(9): 868-872. |
[6] | Zhong Jiemin, Li Wei, Zhang Shujuan, Yang Yan, Xue Rujun, Li Xinyi, Ke Yanan, Chen Xiaoyin, Chen Quan. Comparison of the efficacy and safety of nanomicroneedle- versus ultrasound-mediated delivery of tranexamic acid for the treatment of melasma: a randomized controlled study [J]. Chinese Journal of Dermatology, 2025, 58(9): 829-833. |
[7] | Guliziba·Tuersun, Zhao Yanan, Wang Hongjuan, Kang Xiaojing, Qu Yuanyuan. Efficacy of autologous melanocyte transplantation combined with 308-nm light-emitting diode phototherapy at escalating doses in the treatment of refractory stable vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2025, 58(9): 852-856. |
[8] | Zhan Jinshan, Xuan Xiuyun, Cao Juanmei, Chen Fangqi, Huang Changzheng. Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis [J]. Chinese Journal of Dermatology, 2025, 58(8): 785-788. |
[9] | Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024 [J]. Chinese Journal of Dermatology, 2025, 58(8): 777-780. |
[10] | Acne Study Group of China Dermatologist Association, Dermatology Professional Committee of Chinese Research Hospital Association, Acne Study Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine. Chinese expert consensus on clinical severity grading and therapeutic evaluation of acne vulgaris (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(8): 709-714. |
[11] | Bai Qi, Zhu Mingfang, Wu Qingting, Ji Xiaotian, Yang Huiyi, Ma Liping, Zhou Jiaxin. Effect of sinomenine on skin lesions in 2,4-dinitrochlorobenzene-induced atopic dermatitis-like mouse models [J]. Chinese Journal of Dermatology, 2025, 58(8): 759-766. |
[12] | Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the diagnosis and treatment of localized scleroderma (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(8): 699-708. |
[13] | Lin Jinran, Leong Hiochon, Liu Qingmei, Wu Wenyu. Androgenetic alopecia and metabolic syndrome: from mechanisms to treatment strategies [J]. Chinese Journal of Dermatology, 2025, 58(7): 591-594. |
[14] | Wang Qin, Lin Jinran, Liu Qingmei, Wu Wenyu, . Oral minoxidil in the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 653-656. |
[15] | Hair Research Group, Chinese Society of Dermatology. Chinese expert consensus on the diagnosis and treatment of lichen planopilaris/frontal fibrosing alopecia (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(7): 583-590. |
|